logo
Share SHARE
FONT-SIZE Plus   Neg

Genentech's Obinutuzumab Gets Priority Review For Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration or FDA has accepted Genentech's Biologics License Application or BLA for obinutuzumab or GA101 and granted Priority Review in the treatment of chronic lymphocytic leukemia or CLL, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 study. This acceptance follows the GA101 FDA Breakthrough Therapy Designation, received in May 2013. The FDA confirmed that the action date is December 20, 2013.

The FDA is assessing data from the pivotal Phase III CLL11 study, which found that GA101 showed a statistically significant 86 percent reduction in the risk of disease worsening or death when combined with chlorambucil chemotherapy compared to chlorambucil alone in previously untreated people with CLL and co-existing medical conditions. In CLL11, no new safety signals were detected for GA101.

GA101, an investigational medicine designed to attack cells that have a certain marker on their surface, is currently being investigated in a large clinical program, including multiple head-to-head Phase III trials versus rituximab in indolent non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. CLL is one of the most common forms of blood cancer and in 2013, it is anticipated that there would be about 5,000 deaths from CLL in the U.S.

Genentech, a member of the Roche Group (RHHBY.PK), has headquarters in South San Francisco, California.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Costco Wholesale Corp. (COST), an international chain of membership warehouses, is scheduled to report its first-quarter results on Thursday. Analysts polled by Thomson Reuters estimate earnings of $1.34 per share on revenue of $31.47 billion. Last year, the company reported earnings of $1.24 per share and revenue of $28.1 billion. Shares of Industria de Diseño Textil SA or Inditex were gaining around 4 percent in the morning trading in Spain after the fashion retailer reported Wednesday higher profit and sales in the nine-month period. Regarding the fourth-quarter 2017 trading, the company noted that online and offline store sales increased 13 percent in local currency terms between November 1 and December 11. PepsiCo has placed reservations for 100 Tesla Semi trucks, reports said. The order booking, which is said to be the largest public one to date, is likely to cost the snack and beverage giant around $2 million. Tesla's electric commercial trucks is expected to begin production in 2019. It requires $20,000 for reservation for a truck, as per reports.
comments powered by Disqus
Follow RTT